TABLE 1.
Demographics and testing characteristics among patients who received a COVID‐19 test within the first 14 days of testing
| Demographics and testing | SARS‐CoV‐2 positive, N = 51; n (%) | SARS‐CoV‐2 negative, N = 537; n (%) | All SARS‐CoV‐2 tests, N = 588; n (%) |
|---|---|---|---|
| Age group | |||
| <18 | 0 (0.0) | 2 (0.3) | 2 (0.3) |
| 18–64 | 44 (86.3) | 438 (81.6) | 482 (82.0) |
| 65+ | 7 (13.7) | 97 (18.1) | 104 (17.7) |
| Sex | |||
| Male | 29 (56.9) | 265 (49.3) | 294 (50.0) |
| Female | 22 (43.1) | 272 (50.7) | 294 (50.0) |
| Influenza A/B test | 42 (82.4) | 458 (85.3) | 500 (85.0) |
| RPNA test | 27 (52.9) | 326 (60.7) | 353 (60.0) |
| Influenza A/B or RPNA test | 46 (90.2) | 494 (92.0) | 540 (91.8) |
| Testing | |||
| SARS‐CoV‐2 only | 5 (9.8) | 43 (8.0) | 48 (8.2) |
| SARS‐CoV‐2 and influenza | 19 (37.3) | 168(31.3) | 187 (31.8) |
| SARS‐CoV‐2 and RPNA | 4 (7.8) | 36 (6.7) | 40 (6.8) |
| SARS‐CoV‐2, influenza, and RPNA | 23 (45.1) | 290 (54.0) | 313 (53.2) |
COVID‐19, coronavirus disease 2019; RPNA, upper respiratory pathogen nucleic acid detection.